The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543

Journal of Pharmacology and Experimental Therapeutics

Volumn 285, Issue 3, 1998, Pages 946-954

  Showell, H J ^a   Conklyn, M J ^a   Alpert, R ^a   Hingorani, G P ^a   Wright, K F ^a   Smith, M A ^a   Stam, E ^b   Salter, E D ^a   Scampoli, D N ^a   Meltzer, S ^a   Reiter, L A ^a   Koch, K ^a   Piscopio, A D ^a   Cortina, S R ^a   Lopez Anaya, A ^a   Pettipher, E R ^a   Milici, A J ^a   Griffiths, R J ^a  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 BENZYL 4 HYDROXYCHROMAN 7 YL) 4 TRIFLUOROMETHYL BENZOIC ACID; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; DRUG SCREENING; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ARTHRITIS; CELL ADHESION MOLECULES; CHEMOTACTIC FACTORS; CHEMOTAXIS; CHROMANS; COLLAGEN; DRUG EVALUATION, PRECLINICAL; HUMANS; INTERLEUKIN-1; LEUKOTRIENE B4; MACROPHAGE-1 ANTIGEN; MICE; MICE, INBRED BALB C; MONOCYTES; NEUTROPHILS; PROSTAGLANDINS; SPLEEN; ZYMOSAN;

EID: 7144227269     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
2. 4 receptor site. J Pharmacol Exp Ther 236:126-132.
3. 50) of an enzyme reaction. Biochem Pharmacol 22:3099-3108.
4. Cohen N and Yagaloff KA (1994) Recent progress in the development of leukotriene B4 antagonists. Curr Opin Invest Drugs 3:13-22.
5. Collawn C, Rubin P, Perez N, Bobadilla J, Cabrera G, Reyes E, Borovoy J and Kershenobich D (1992) Phase II study of the safety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis. Am J Gastroenterol 87:342-346.
6. Conklyn MJ, Neote K and Showell HJ (1996) Chemokine-dependent upregulation of CD11b on specific leukocyte subpopulations in human whole blood: Effect of anticoagulant on RANTES and MIP-1β stimulation. Cytokine 8:762-766.
7. de Jong EMGJ, van Vlijmen IMMJ, Scholte JCM, Buntinx A, Friedman B, Tanaka W, van der Kerkhof PCM (1991) Clinical and biochemical effects of an oral leukotriene biosynthesis inhibitor (MK889) in psoriasis. Skin Pharmacol 4:278-285.
8. Djuric SW and Fretland DJ (1989) 12(R)- and 12(S)-hydroxyeicosatetraenoic acids: Chemistry, biology and pharmacology. Prostaglandins Leukot Essent Fatty Acids 38:215-228.
9. Djuric SW, Fretland DJ and Penning TD (1992) The leukotriene B4 receptor antagonists - A most discriminating class of antiinflammatory agent? Drugs Future 17:819-830.
10. 4 receptor antagonist, LY 293111, on allergen induced responses in asthma. Thorax 51:1178-1184.
11. Ferrante A and Thong YH (1978.) A rapid one-step procedure for purification of mononuclear and polymorphonuclear leukocytes from human blood using a modification of the Hypaque-Ficoll technique. J Immunol Methods 24:389-393.
12. Findlay SR, Barden JM, Easley CB and Glass M (1992) Effect of the oral leukcotriene antagonist ICI 204,219 on antigen-induced bronchoconstriction in subjects with asthma. J Allergy Clin Immunol 89:1040-1045.
13. Ford-Hutchinson AW (1993) 5-lipoxygenase activation in psoriasis: A dead issue. Skin Pharmacol 6:292-297.
14. 4 in inflammation. Crit Rev Immunol 10:1-12.
15. 4 receptor antagonist, SC-53228. Effects on acute colonic inflammation and hepatic function in rodents. Inflammation 19:503-515.
16. 4 receptor antagonist in colitic cotton-top tamarins. Gut 37:702-707.
17. 4 receptor antagonist research. Exp Opin Ther Patents 6:21-28.
18. 4-receptor interaction suppresses eosinophil infiltration and disease pathology in a murine model of experimental allergic encephalomyelitis. J Exp Med 183:1893-1989.
19. Griffiths RJ, Smith, M-A, Roach ML, Stock JL, Stam EJ, Milici AJ, Scampoli DN, Eskra JD, Byrum RS, Koller BH and McNeish JD (1997) Collagen-induced arthritis is reduced in 5-lipoxygenase activating protein deficient mice. J Exp Med 185:1123-1129.
20. 4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci USA 92:517-521.
21. Hammarström S, Hamberg M, Samuelsson B, Duell EA, Stawiski M and Vorhees JJ (1975) Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2 and prostaglandin F2 in epidermis of psoriasis. Proc Natl Acad Sci USA 72:5130-5134.
22. Harrison KA and Murphy RC (1995) Isoleukotrienes are biologically active free radical products of lipid peroxidation. J Biol Chem 29:17273-17278.
23. Harvath L, McCall CE, Bass DA and McPhail LC (1987) Inhibition of human neutrophil chemotaxis by the protein kinase inhibitor, 1-(5-isoquinolinesulfonyl)piperazine. J Immunol 139:3055-3061.
24. Hawkey CJ, Dube LM, Rountree LV, Liunen PJ, Lancaster JF and the European study group for ulcerative colitis (1997) A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology 112:718-724.
25. Henderson WR (1994) The role of leukotrienes in inflammation. Ann Intern Med 121:684-697.
26. Irvin GG, Tu, Y-P, Sheller JR and Funk CD (1997) 5-lipoxygenase products are necessary for ovalbumin-induced airway responses in mice. Am J Physiol 272: L1053-L1056.
27. Koch, K. (1993) WO 93/15067.
28. 4 antagonist with oral activity in the murine collagen induced arthritis model. J Med Chem 37:3197-3199.
29. Lewis RA, Austen, K-F and Soberman RJ (1990) Leukotrienes and other products of the 5-lipoxygenase pathway, biochemistry and relation to pathobiology in human diseases. N Engl J Med 323:645-655.
30. 4 binding to human neutrophils. Prostaglandins 28:837-849.
31. 4 receptor antagonist CP-105696 in man following single oral administration. Br J Clin Pharmacol 45:115-121.
32. Nasser SMS, Bell GS, Hawksworth RJ, Spruce KE, MacMillan R, Williams AJ, Lee TH and Arm JP (1994) Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic response. Thorax 49:743-748.
33. 4: Implications for the regulation of inflammatory responses. Br J Pharmacol 110:423-427.
34. 4 antagonist L648,051. Allergy 47:604-609.
35. Roberts WG, Simon TJ, Berlin RG, Haggitt RG, Snyder ES, Stenson WF, Hananer SB, Reagan JE, Cagliola A, Tanaka WK, Simon S and Berger ML (1997) Leukotrienes in ulcerative colitis: Results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology 112:725-732.
36. Rot A (1991) Chemotactic potency of recombinant human neutrophil attractant/ activating protein-1 (Interleukin-8) for polymorphonuclear leukocytes of different species. Cytokine 3:21-27.
37. Samuelsson B (1983) Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science 220:568-575.
38. 4 receptor antagonists recent clinical developments. Exp Opin Invest Drugs 5:73-77.
39. Schild HO (1947) pA, a new scale for the measurement of drug antagonism. Br J Pharmacol Chemother 2:189-206.
40. 4 antagonist CP-105,696 on murine LTB4 receptors in vitro. Br J Pharmacol 117:1127-1132.
41. 4 antagonist CP-105,696. J Pharmacol Exp Ther 273:176-186.
42. 4 receptor antagonist SC-53228 on ozone-induced airway hyperresponsiveness and inflammation in dogs. Am J Respir Crit Care Med 152:1443-1448.
43. Taylor IK, O'Shaughnessy KM, Fuller RW and Dollery CT (1991) Effect of cysteinyl leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet 337:690-694.
44. 4 antagonism in a primate model of asthma. J Clin Invest 97:381-387.
45. Turner CR, Smith WB, Andresen CJ, Eggler JF and Watson JW (1996b) The effect of 5-lipoxygenase inhibition on ascaris antigen (Ag)-induced responses in atopic monkeys. Inflamm Res 45:42-49.
46. Weinblatt ME, Kremer JM, Coblyn JS, Helfgolt S, Muier AL, Petrillo G, Henson B, Rubin P and Sperling R (1992) Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. J Rheumatol 19:1537-1541.
47. Woolard PM (1986) Stereochemical differences between 12-hydroxy-5,8,10,14-eicosatetraenoic acid in platelets and psoriatic lesions. Biochem Biophys Res Commun 136:169-176.